Metropolitan Life Insurance Company (MetLife)’s Adamas Pharmaceuticals ADMS Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio ADMS Stock Details ADMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-7,606	Closed	-$152K	–	2590
2018 Q3	$152K	Hold	7,606	–	–	﹤0.01%	2196
2018 Q2	$196K	Buy	7,606 +2,293	+43%	+$63.5K	﹤0.01%	1955
2018 Q1	$127K	Hold	5,313	–	–	﹤0.01%	2170
2017 Q4	$180K	Sell	5,313 -5,115	-49%	-$143K	﹤0.01%	1975
2017 Q3	$221K	Hold	10,428	–	–	﹤0.01%	2218
2017 Q2	$182K	Hold	10,428	–	–	﹤0.01%	2395
2017 Q1	$182K	Hold	10,428	–	–	﹤0.01%	2328
2016 Q4	$176K	Hold	10,428	–	–	﹤0.01%	2430
2016 Q3	$171K	Hold	10,428	–	–	﹤0.01%	2433
2016 Q2	$158K	Buy	+10,428	New	+$172K	﹤0.01%	2491
2015 Q4	–	Sell	-7,926	Closed	-$133K	–	2649
2015 Q3	$133K	Hold	7,926	–	–	﹤0.01%	2527
2015 Q2	$208K	Buy	+7,926	New	+$154K	﹤0.01%	2376

Other funds holding ADMS

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s ADMS Position: Q4 2018 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Adamas Pharmaceuticals (ADMS) in Q4 2018, closing a stake of 7,606 shares — an estimated $152K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in ADMS in Q2 2015 and held it in 12 quarters. The position peaked at $221K in Q3 2017. 98 funds tracked by Wall St. Rank hold ADMS as of Q4 2018.

Metropolitan Life Insurance Company (MetLife) reported no remaining Adamas Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
Metropolitan Life Insurance Company (MetLife) sold 7,606 Adamas Pharmaceuticals shares in Q4 2018, an estimated $152K.
Metropolitan Life Insurance Company (MetLife) first reported a position in Adamas Pharmaceuticals in Q2 2015 and held it in 12 quarters.
Metropolitan Life Insurance Company (MetLife)'s Adamas Pharmaceuticals position peaked at $221K in Q3 2017.
98 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q4 2018.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q4 2018, filed 14 Feb 2019.